Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study

Acta Obstetricia Et Gynecologica Scandinavica
Ting-Chen ChangSong-Nan Chow

Abstract

To compare the effect of hormone replacement therapy (HRT) using estrogen plus dydrogesterone or estrogen plus medroxyprogesterone acetate (MPA) on the risk factors for coronary heart disease (CHD) in postmenopausal women. A randomized, prospective 1-year clinical trial was designed. All of the postmenopausal women (n = 279) received sequential conjugated equine estrogen (CEE) at a dose of 0.625 mg/day for 25 days (days 1-25) of each month. These women were also randomly assigned to receive either dydrogesterone 10 mg/day (E + D group, n = 140) or MPA 5 mg/day (E + P group, n = 139) for 14 days (days 12-25) of each month. Serum biochemical markers, lipoproteins, plasma prothrombin time (PT), partial prothrombin time (PPT) and antithrombin III-antigen (ATIII-Ag) were analyzed at baseline, and after 6 and 12 months of treatment. Liver function, renal function, PT and PPT did not change significantly during the 12-month trial. The E + D group had a more pronounced increase in high density lipoprotein cholesterol (HDL-C) than the E + P group (10.6% vs. 2.7%) after 12 months of treatment (p < 0.05). Both groups showed reduced concentrations of total cholesterol (T-CHO), low density lipoprotein cholesterol (LDL-C) and ATIII, whereas ...Continue Reading

References

Jan 1, 1978·Methods in Enzymology·J A Buege, S D Aust
Dec 15, 1992·Annals of Internal Medicine·D GradyS R Cummings
Jan 1, 1990·British Journal of Haematology·T W MeadeY Stirling
Dec 1, 1989·American Journal of Obstetrics and Gynecology·M Notelovitz
Apr 14, 1989·JAMA : the Journal of the American Medical Association·E Barrett-ConnorM H Criqui
Jan 1, 1986·British Journal of Obstetrics and Gynaecology·G LaneM I Whitehead
Jun 1, 1988·American Journal of Obstetrics and Gynecology·J C La Rosa
Nov 28, 1986·JAMA : the Journal of the American Medical Association·W P CastelliW B Kannel
Jul 1, 1985·Obstetrical & Gynecological Survey·F K Beller, C Ebert
Jul 15, 1985·American Journal of Obstetrics and Gynecology·J P Realini, J W Goldzieher
Jul 1, 1980·British Journal of Obstetrics and Gynaecology·M E PatersonT P Whitehead
Oct 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·L C LyuE J Schaefer
Mar 15, 1993·Annals of Internal Medicine·K H PoldermanL J Gooren
Mar 1, 1997·Obstetrics and Gynecology·C M KesslerJ C LaRosa
Apr 16, 1998·Acta Obstetricia Et Gynecologica Scandinavica·C E BondukiG R Lima
Jul 27, 1999·The Journal of Steroid Biochemistry and Molecular Biology·R Sitruk-Ware
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators

❮ Previous
Next ❯

Citations

Apr 4, 2006·Journal of Medicinal Food·Edralin A LucasBahram H Arjmandi
Nov 22, 2017·Lipids in Health and Disease·Yifan Jiang, Weijie Tian
May 9, 2006·Journal of Cardiovascular Pharmacology·George E ChristodoulakosGeorge C Creatsas

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.